Advertisment
Indian Journal of Nephrology About us |  Subscription |  e-Alerts  | Feedback | Login   
  Print this page Email this page   Small font sizeDefault font sizeIncrease font size
 Home | Current Issue | Archives| Ahead of print | Search |Instructions |  Editorial Board  

Users Online:685

Official publication of the Indian Society of Nephrology
  Search
 
 ~ Next article
 ~ Previous article 
 ~ Table of Contents
  
 ~  Similar in PUBMED
 ~  Search Pubmed for
 ~  Search in Google Scholar for
 ~  Article in PDF (262 KB)
 ~  Citation Manager
 ~  Access Statistics
 ~  Reader Comments
 ~  Email Alert *
 ~  Add to My List *
* Registration required (free)  

 
   References
   Article Figures

 Article Access Statistics
    Viewed1347    
    Printed74    
    Emailed0    
    PDF Downloaded159    
    Comments [Add]    

Recommend this journal

 


 
LETTER TO EDITOR
Year : 2009  |  Volume : 19  |  Issue : 2  |  Page : 82
 

Posttransplant lymphoproliferative disease presenting as jejunal perforation


1 Department of Nephrology, Sri Venkateswara Institute of Medical Sciences, Tirupati, India
2 Department of Surgical Gastroenterology, Sri Venkateswara Institute of Medical Sciences, Tirupati, India
3 Department of Medical Oncology, Sri Venkateswara Institute of Medical Sciences, Tirupati, India
4 Department of Pathology, Sri Venkateswara Institute of Medical Sciences, Tirupati, India

Date of Web Publication10-Jul-2009

Correspondence Address:
V Sivakumar
Department of Nephrology, Sri Venkateswara Institute of Medical Sciences (SVIMS), Tirupati
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0971-4065.53330

Rights and Permissions



How to cite this article:
Krishna K C, Sivaramakrishna G, Kumar P M, Kannan T, Reddy K M, Sivakumar V. Posttransplant lymphoproliferative disease presenting as jejunal perforation. Indian J Nephrol 2009;19:82

How to cite this URL:
Krishna K C, Sivaramakrishna G, Kumar P M, Kannan T, Reddy K M, Sivakumar V. Posttransplant lymphoproliferative disease presenting as jejunal perforation. Indian J Nephrol [serial online] 2009 [cited 2020 Nov 26];19:82. Available from: https://www.indianjnephrol.org/text.asp?2009/19/2/82/53330


Sir,

A forty-nine year-old male underwent live related renal transplantation thirteen years ago for end stage renal disease secondary to bilateral vesicoureteric reflux. He was on prednisolone 10 mg per day and azathioprine 125 mg per day for maintenance immunosuppression. He presented with pain in his abdomen and vomiting that had been prevalent since the past day. Evaluation was suggestive of hollow viscous perforation which was confirmed by computed tomography of the abdomen. As laparotomy revealed a perforation with growth in the jejunum, a jejunal segment resection was done followed by jejunojejunal anastamosis. Histopathological investigation revealed that the growth was a diffuse, large B cell lymphoma [Figure 1]. Immunohistochemistry confirmed it to be a B cell variant of diffuse large cell NonHodgkin's lymphoma of the small bowel. Viral serology showed significant Epstein barr virus (viral capsid antigen) IgM and Epstein barr virus (nuclear antigen) IgG levels being normal. The patient was maintained on CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) regimen by a medical oncologist.

Renal transplant recipients carry a three to five fold higher risk of malignancy as compared to healthy people. Posttransplant lymphoproliferative disease (PTLD) is second only to skin cancers in contributing to 12% of posttransplant malignancies and its incidence increases with time. [1] The risk of developing PTLD is highest within the first year after the transplant, and the probability decreases thereafter. [2] The incidence increases with the age of the patient and the duration and cumulative dose of immunosuppressive therapy. It is associated with high morbidity and mortality. Cumulative doses and longer duration of systemic glucocorticoids and azathioprine increase the incidence of nonHodgkin's lymphoma (NHL).[3] The single most important risk factor for developing PTLD is EBV infection. This association is well established and 80-90% of PTLD cases are associated with primary EBV infection or reactivation of previously acquired EBV. [4]

Most cases of PTLD occur as nodal diseases, but they can present with localized symptoms involving organs such as the gastrointestinal tract, lungs, skin, liver, central nervous system, and infiltrative lesions in the allograft. Extranodal involvement occurs in more than 50% of the cases. The gastrointestinal tract is predominantly involved with an increased propensity for ulceration and perforation. [5] In our patient, the points of interest were: a) presentation as perforation, b) the neoplastic growth resected turning out as a diffuse B cell variant of nonHodgkin's lymphoma with positive Epstein barr viral serology.

 
  References Top

1.Vasudev B, Hariharan S. Cancer after transplantation. Curr Opin Nephrol Hypertens 2007;16:523-8.  Back to cited text no. 1  [PUBMED]  [FULLTEXT]
2.Nalesnik MA. Posttransplantation lymphoproliferative disorders (PTLD): Current perspectives. Semin Thorac Cardiovasc Surg 1996;8:139-48.  Back to cited text no. 2  [PUBMED]  
3.Kauffman HM, Cherikh WS, McBride MA, Cheng Y, Hanto DW. Post transplant de novo malignancies in renal transplant recipients: The past and the present. Trans Int 2006;19:607-20.  Back to cited text no. 3    
4.Young L, Alfieri C, Hennessy K, Evans H, O'Hara C, Anderson KC, et al . Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 1989;321:1080-5.  Back to cited text no. 4  [PUBMED]  
5.Dodd GD 3 rd , Greenler DP, Confer SR. Thoracic and abdominal manifestations of lymphoma occurring in the immunocompromised patient. Radiol Clin North Am 1992; 30:597-610.  Back to cited text no. 5    


    Figures

  [Figure 1]



 

Top
Print this article  Email this article
Previous article Next article

    

Indian Journal of Nephrology
Published by Wolters Kluwer - Medknow
Online since 20th Sept '07